<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the efficacy of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> pulse therapy (<z:chebi fb="0" ids="38559">CYP</z:chebi>) for refractory <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> except for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:hpo ids='HP_0000123'>nephritis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-five patients were included in <z:hpo ids='HP_0000001'>all</z:hpo>, that is 9 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 10 with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), 7 with <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e>/<z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> (PM/DM), 2 with progressive systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (<z:chebi fb="17" ids="53277">PSS</z:chebi>), 2 with anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome (APS), 1 with <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>), 1 with <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JRA</z:e>), 1 with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> (BD), 1 with Wegener's <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">WG</z:e>) and 1 with allergic granulomatous <z:mp ids='MP_0001864'>angiitis</z:mp> (AGA) </plain></SENT>
<SENT sid="2" pm="."><plain>Moderate to marked improvement was noted in 4 patients with SLE (2 with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> and 2 with <z:hpo ids='HP_0002633'>vasculitis</z:hpo>), 7 with RA (2 with interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo>:IP, 2 with <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and 2 with refractory <z:hpo ids='HP_0001369'>arthritis</z:hpo>), 4 with PM/DM (2 with IP and 2 with refractory <z:hpo ids='HP_0100614'>myositis</z:hpo>), 1 PSS with IP, 2 APS with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, 1 JRA with <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and BD with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disturbance </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, adverse reactions were observed in 9 out of 35 patients (25.8%) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="38559">CYP</z:chebi> should apply in the treatment for such refractory <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> as <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disturbance, <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, IP and <z:hpo ids='HP_0001973'>autoimmune thrombocytopenia</z:hpo> </plain></SENT>
</text></document>